Stockscreener 앱 받기
224.13
3.98%
-9.29
시간 외 거래:
224.89
0.76
+0.34%
전일 마감가:
$233.42
열려 있는:
$231.125
하루 거래량:
9.35M
Relative Volume:
1.64
시가총액:
$396.12B
수익:
$59.64B
순이익/손실:
$2.36B
주가수익비율:
169.12
EPS:
1.3253
순현금흐름:
$19.68B
1주 성능:
-1.91%
1개월 성능:
+0.45%
6개월 성능:
+18.11%
1년 성능:
+25.56%
1일 변동 폭
$223.12
$231.54
1주일 범위
$217.86
$237.04
52주 변동 폭
$164.39
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
224.13 | 412.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,085.19 | 991.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.75 | 499.90B | 92.15B | 25.12B | 20.46B | 10.36 |
|
MRK
Merck Co Inc
|
110.99 | 269.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.46 | 272.43B | 54.45B | 14.42B | 17.15B | 7.333 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Sues Over Bids To Market Generic Migraine Drugs - Law360
Merck in Deal Talks With Biotech Revolution Medicines, FT Says - Bloomberg.com
Key facts: AbbVie revises EPS guidance; negotiates $20B acquisition - TradingView — Track All Markets
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders - TechStock²
AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial - Benzinga
AbbVie: The Dividend Does Not Lie (NYSE:ABBV) - Seeking Alpha
Merck (MRK) Upgraded by Wolfe Research, AbbVie (ABBV) Downgraded - GuruFocus
Merck upgraded, AbbVie downgraded at Wolfe (MRK:NYSE) - Seeking Alpha
AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail - Sherwood News
AbbVie Flags $1.3B Charge, Cuts Fourth-Quarter EPS Outlook - Yahoo Finance
AbbVie, Revolution Medicines Stocks Fall After Drugmaker Denies Takeover Report - Barron's
Aug Big Picture: Can AbbVie Inc. stock continue upward trendDividend Hike & Accurate Trade Setup Notifications - ulpravda.ru
Lockheed, Northrop, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked inWolfe - Investing.com India
AbbVie (ABBV) Stock Falls After Company Denies Revolution Medicines Buyout Talks - Blockonomi
Northrop, Lockheed, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story? - Yahoo Finance
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down - TechStock²
Revolution Medicines dips after AbbVie denies takeover talks - TradingView — Track All Markets
AbbVie (ABBV) Stock Drops as Company Denies Revolution Medicines Acquisition Reports - CoinCentral
AbbVie Lowers Q4, 2025 Adjusted EPS Guidance - MarketScreener
Why Revolution Medicines Shares Are Sliding After Hours On Wednesday - Benzinga
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
AbbVie (ABBV) Projects Q4 Earnings Impact from $1.3 Billion Char - GuruFocus
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie flags $1.3B IPR&D charge, warns of Q4 earnings pressure (ABBV:NYSE) - Seeking Alpha
Revolution Medicines Stock Pre-Market (-6.0%): AbbVie Denies Acquisition Talks - Trefis
AbbVie Denies Media Reports of Talks to Buy Revolution Medicines - MarketScreener
What's Happening With Cancer Biotech Erasca Shares This Thursday? - Bitget
AbbVie denies media reports of talks to buy Revolution Medicines - WTVB
Exclusive | Revolution Medicines Draws Takeover InterestWSJ - The Wall Street Journal
Revolution Medicines Stock Drops After-Hours On AbbVie Denying Acquisition Talks - Stocktwits
Stock Movers: Jeffries, AbbVie, Raytheon - Bloomberg.com
AbbVie2025 adjusted EPS guidance range $9.90$9.94SEC filing - MarketScreener
Revolution Medicines (RVMD) Shares Plunge After AbbVie Denies Acquisition Talks - GuruFocus
Abbvie denies WSJ report of talks to buy biotech player Revolutions Medicine - Crain's Chicago Business
AbbVie (ABBV) Denies Acquisition Talks with Revolution Medicines - GuruFocus
AbbVie (ABBV) Denies Discussions with Revolution Medicines - GuruFocus
AbbVie Says It’s Not in Talks to Buy Revolution Medicines - Bloomberg.com
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
AbbVie reports $1.3 billion Q4 expense from acquired research deals - StreetInsider
Revolution Medicines (RVMD) Surges on AbbVie Acquisition Talks - GuruFocus
AbbVie (ABBV) Nears Acquisition Deal with Revolution Medicines - GuruFocus
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
AbbVie M&A Buzz Sends Revolution Medicines RVMD Above $100, ABBV Stock $230+ - FXLeaders
AbbVie (ABBV) Nears Acquisition of Cancer-Drug Firm Revolution M - GuruFocus
AbbVie (ABBV) Nears Acquisition of Revolution Medicines in a Maj - GuruFocus
American pharmaceutical giant in advanced negotiations for a major acquisition - medwatch.com
Exclusive | AbbVie Near Deal for Revolution MedicinesWSJ - The Wall Street Journal
AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition - MarketScreener
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports - TradingView — Track All Markets
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
2.20%
자본화:
|
볼륨(24시간):